Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $18.21M rose 144.9% year over year, ahead of the +60.0% change in trailing-twelve-month research & development. Sequentially, it rose 7.5% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.
Context
- Research & development amounted to 339.4% of revenue in FY2025, down 61.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +144.9% holds above the trailing-twelve-month pace of +60.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 44.49M USD
- Year-over-year change
- +10.0%
- 4-year CAGR
- -10.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.49M | +10.0% |
| FY2024 | 2024-12-31 | 40.45M | -53.3% |
| FY2023 | 2023-12-31 | 86.66M | +5.8% |
| FY2022 | 2022-12-31 | 81.88M | +18.9% |
| FY2021 | 2021-12-31 | 68.84M | — |
Research & Development vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +60.0% is the 3rd highest of 10, against a peer median of -7.1%.
- Research & development amounts to 314.8% of revenue for TNXP, versus a peer median of 1590.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $100.48M USD | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $88.91M USD | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $69.93M USD | +20.4% | +34.8% | — | |
| LTM Mar 2026 | $65.43M USD | +123.8% | +118.4% | — | |
| LTM Mar 2026 | $55.26M USD | +60.0% | -18.4% | 314.8% | |
| LTM Mar 2026 | $55.01M USD | +74.4% | +17.0% | 93235.6% | |
| FY2025 | €43.62M EUR | -16.1% | -5.5% | 1565.1% | |
| LTM Mar 2026 | $37.82M USD | -33.6% | -23.5% | 3297.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M USD | -29.5% | +13.5% | — |
| LTM Mar 2026 | $16.56M USD | +5.5% | -23.1% | 928.4% | |
| Peer median (excluding TNXP) | — | -7.1% | -0.2% | 1590.8% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.77M | 10.09M | 13.11M |
| Cost of Revenue | 0 | 0 | 4.74M | 7.77M | 8.57M |
| Gross Profit | 0 | 0 | 3.03M | 2.33M | 4.54M |
| Gross Margin | — | — | 39.0% | 23.1% | 34.7% |
| Research & Development | 68.84M | 81.88M | 86.66M | 40.45M | 44.49M |
| Selling, General & Admin | 23.47M | 30.22M | 34.75M | 40.1M | 85.76M |
| Operating Expenses | 92.31M | 112.09M | 121.41M | 139.03M | 130.25M |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBITDA | (92.24M) | (108.97M) | (112.37M) | (74.32M) | (122.01M) |
| EBITDA Margin | — | — | -1446.5% | -736.3% | -930.9% |
| Operating Income | (92.31M) | (112.09M) | (118.38M) | (136.7M) | (125.7M) |
| Operating Margin | — | — | -1523.9% | -1354.3% | -959.1% |
| Interest Income | 25K | 1.87M | 0 | 0 | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 89K |
| Other Income / Expenses | 25K | 1.87M | 1.72M | 6.67M | 1.68M |
| Income Before Tax | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Pre-Tax Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Net Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (Basic) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| EPS (Diluted) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| Weighted Avg Shares | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
| Weighted Avg Shares (Diluted) | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.